(ISSN 2638-1311)
OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.7 weeks; Submission to Acceptance: 17.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)
Special Issue
Research on Neurodegenerative Diseases
Submission Deadline: December 15, 2020 (Open) Submit Now
Guest Editor
Douglas G. Walker, PhD
Special Contract Professor, Molecular Neuroscience Research Center, Shiga University of Medical Science, Otsu 520-2192, Japan
Research Interests: Alzheimer’s disease; Parkinson’s disease; neurodegenerative diseases
About This Topic
It is with pleasure that we are inviting submissions for this special issue entitled “Research on Neurodegenerative Diseases”. This is a broad title but it is timely for researchers to discuss their hypotheses, results and reviews on the current state of the field with emphasis on new research approaches. Neurodegenerative diseases remain one of the most significant causes of morbidity and mortality, particularly in the aging populations. Despite years of biological and medical research, there are still an unfilled need for new and effective therapies for diseases such as Alzheimer’s disease, Parkinson’s disease, Dementia with Lewy bodies, stroke, vascular dementia and multiple sclerosis. It is timely to consider whether current targets such as amyloid beta, tau, inflammation, alpha synuclein amongst others need to be reconsidered, and whether immunotherapy is likely to be effective. With the huge increase in RNA expression and single nucleotide polymorphism data, consideration how these data have advanced therapy development is also warranted. Similarly, there is a need to consider how the use of induced pluripotent stem cells has advanced our understanding of neurodegeneration.
Manuscript Submission Information
Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (geriatrics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.
Welcome your submission!
Publication
Study of the Development of Carotid Artery Atherosclerosis upon Oxidative Stress using Infrared Spectroscopy and Scanning Electron MicroscopyAbstract In the present study, Fourier-transform infrared (FTIR) spectroscopy and Scanning Electron Microscopy (SEM) were used to investigate the formation and development of carotid artery atherosclerosis. The FTIR spectra showed that with the progression of atheromatic plaque formation, the collagen changed its native structure from [...] |
Regulation of Membrane Phospholipid Homeostasis in Neurodegenerative Diseasesby
XinRan Quan
and
Marica Bakovic
Abstract Neurodegenerative diseases (NDs) are a diverse group of neuropathological diseases that are currently incurable due to the irreversible neuronal loss. At the present rate of the world population growth, it is projected that the number of ND cases will double by the year of 2050. With treatments only available for symptom management [...] |
Deep Brain Stimulation – Therapeutic Possibilities in Alzheimer's DiseaseAbstract Alzheimer’s Disease (AD) is the leading cause of dementia worldwide, and represents a significant cause of cognitive decline, disability, and mortality. Ongoing clinical trials continue to investigate β-amyloid targeted therapy with unclear benefit, and we are currently limited to symptomatic treatment. Therefore, there is a [...] |
Molecular Basis of Allogeneic Pluripotent Stem Cell Treatment of a Patient with Sporadic ALSby
Samuel Brennan
,
Matthew Keon
,
Zheng Su
,
Bing Liu
,
Xiao Min Song
,
Thiri Zaw
,
Matthew McKay
,
Donna Pascovici
and
Nitin K. Saksena
Abstract There are no curative strategies for ALS, and as a result the alternative therapies are gaining ground, in particular the stem cell-based therapies which hold a promising future. Here we describe an ALS patient, who by choice, received allogeneic human cord-blood derived multipotent stem cells (MSC) intravenously and intrathecally. This is [...] |
Post-mortem 7.0-Tesla Magnetic Resonance Imaging of the Hippocampus in Amyotrophic Lateral Sclerosisby
Jacques De Reuck
,
Florent Auger
,
Nicolas Durieux
,
Claude-Alain Maurage
,
Vincent Deramecourt
,
Charlotte Cordonnier
,
Florence Pasquier
,
Didier Leys
and
Regis Bordet
Abstract Amyotrophic lateral sclerosis (ALS) is reported to be probably linked to frontotemporal lobar degeneration (FTLD). Since FTLD is characterized by severe frontotemporal degeneration along with hippocampal atrophy (HA), the present study used post-mortem 7.0-tesla magnetic resonance imaging to investigate whether a certain degree of HA occurs [...] |
TOP
Vidhi is a Clinical yoga therapist; mentor for yoga therapy training in Krishnamacharya tradition. She holds a MSc in Public health from Kings College London.
Mirela Olympia Fagarasan Palmer
Luigi Fontana, MD, PhD.jpg)
Zhong-Ting (Justin) is a PhD student from Nanyang Technological University (Singapore). He holds BSc in Applied Chemistry and MSc in Environmental Engineering. He was a R&D researcher of NanoMaterials Technology Pte Ltd in Singapore (2006-2012). His current research interests are functional nanomaterials synthesis & design, and their application into environmental/chemical engineering. He has published near 60 SCI papers in Applied Catalysis B, Chemical Engineering Journal and so on with H-Index 23. He also serviced as reviewers over 40 Journals such as Appl. Catal. B, Water Research, Chem. Eng. J, ACS Applied Materials & Interface, etc. He was honored such as “The Bsic Research Achievment 1st Award of CIESC”, “The ZJUT Fund Breeding Distinguished Young Scholars” etc.
Rolf Teschke studied Medicine in Munich and Marburg, where he finished his MD thesis before starting a residency at the Department of Pathology, University of Marburg. Subsequently and with a fellowship of the Deutsche Forschungsgmeinschaft, he worked at the Bronx VA Hospital/Mount Sinai Hospital in New York during 1972–1975 together with Professor Charles S. Lieber and successfully isolated MEOS and expanded its characterization. Back in Germany, he was at the Heinrich-Heine University in Düsseldorf with a focus on alcoholic liver disease, biochemical drug studies, and clinical intoxications by halogenated aliphatic hydrocarbons, where he became a Professor of Medicine. In 1987, he was offered a chief position and appointed as Director of the Medical Department II, City Hospital Hanau, Teaching Hospital of the Johann Wolfgang Goethe University Frankfurt/Main. His clinical and research interests are on liver injury by drugs and herbs including causality assessment by RUCAM in close association with Dr. Gaby Danan in Paris. A perfect cooperation exists also with Professor Tran Dang Xuan of the University of Hiroshima, Japan. Finally, he is the author of more than 275 publications including books and book chapters, and he is editor in chief of scientific journals and member of editorial boards.